This article is reserved for members

Already a member?

Log In

Not a member ?

Free registration
Medprin Regenerative Medical Technologies Co., Ltd. Reports Earnings Results for the First Quarter Ended March 31, 2024 CI
Medprin Regenerative Medical Technologies Co., Ltd. Reports Earnings Results for the Full Year Ended December 31, 2023 CI
Tranche Update on Medprin Regenerative Medical Technologies Co., Ltd.'s Equity Buyback Plan announced on February 23, 2024. CI
Medprin Regenerative Medical Technologies Co., Ltd. announces an Equity Buyback for CNY 20 million worth of its shares. CI
Medprin Regenerative Medical Technologies Co., Ltd. authorizes a Buyback Plan. CI
Medprin Regenerative Medical Technologies Co., Ltd. Reports Earnings Results for the Nine Months Ended September 30, 2023 CI
Medprin Regenerative Medical Technologies Co., Ltd. Reports Earnings Results for the Half Year Ended June 30, 2023 CI
Certain A Shares of Medprin Regenerative Medical Technologies Co., Ltd. are subject to a Lock-Up Agreement Ending on 26-JUL-2023. CI
Medprin Regenerative Medical Technologies Co., Ltd. Approves Final Cash Dividend for the Year 2022, Payable on 01 June 2023 CI
Medprin Regenerative Medical Technologies Co., Ltd. Proposes Profit Distribution of Cash Dividend for the Year 2022 CI
Medprin Regenerative Medical Technologies Co., Ltd. Reports Earnings Results for the First Quarter Ended March 31, 2023 CI
Medprin Regenerative Medical Gets Marketing Nod in China for Craniofacial Fixation Plate MT
Medprin Regenerative Medical Technologies Co., Ltd. Reports Earnings Results for the Nine Months Ended September 30, 2022 CI
Medprin Regenerative Medical Technologies Co., Ltd. Reports Earnings Results for the Half Year Ended June 30, 2022 CI
Certain A Shares of Medprin Regenerative Medical Technologies Co., Ltd. are subject to a Lock-Up Agreement Ending on 26-JUL-2022. CI
Medprin Regenerative Medical Technologies to Free Up 2.5% Stake For Trading MT
Medprin Regenerative Medical Technologies Co., Ltd. Approves Profit Distribution Plan for 2021 CI
Medprin Regenerative Medical Technologies Co., Ltd. Announces Profit Distribution for 2021 CI
Medprin Regenerative Medical Technologies Co., Ltd. Reports Earnings Results for the First Quarter Ended March 31, 2022 CI
Medprin Regenerative Medical Technologies Co., Ltd. Reports Earnings Results for the Nine Months Ended September 30, 2021 CI
Medprin Regenerative Medical Technologies Co., Ltd. has completed an IPO in the amount of CNY 250.048697 million. CI
Medprin Regenerative Medical Technologies Co., Ltd. has filed an IPO. CI
Chart Medprin Regenerative Medical Technologies Co., Ltd.
More charts
Medprin Regenerative Medical Technologies Co Ltd is a China-based company principally engaged in the research and development, production and sales of high-performance implantable medical devices. The Company's implanted medical device products include artificial dura mater (spine) patch, cranio-maxillofacial repair products and absorbable hemostatic yarns. 3D printing equipment includes biological 3D printers, resin 3D printers and other related supporting components. Technical services include general technical services and scientific research services. The Company distributes its products both in the domestic market and to overseas markets.
More about the company
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
1
Last Close Price
41.7
Average target price
-
Consensus

Annual profits - Rate of surprise

  1. Stock Market
  2. Equities
  3. 301033 Stock
  4. News Medprin Regenerative Medical Technologies Co., Ltd.
  5. Medprin Regenerative Medical Gets Marketing Nod in China for Craniofacial Fixation Plate